Date Time
New commissioners appointed to Commission on Human Medicines
Professor Amanda Adler, Professor Sandosh Padmanabhan, Professor Steve Cunningham and Professor Yvonne Perrie have been appointed as Commissioners of the CHM for four years, in accordance with the Cabinet Office Code of Governance for Public Appointments.
The CHM provides independent expert advice to ministers on the safety, quality and efficacy of medicines, and on adverse reactions including those reported under the Yellow Card Scheme. It is an advisory non-departmental public body, sponsored by the Department of Health and Social Care.
Sandosh Padmanabhan, Professor of Cardiovascular Genomics and Therapeutics at the University of Glasgow and the University of Toledo, said:
New commissioners appointed to the Commission on Human Medicines
Four new Commissioners will join the Commission on Human Medicines (CHM) on 1 May 2021.
From:
30 April 2021
Professor Amanda Adler, Professor Sandosh Padmanabhan, Professor Steve Cunningham and Professor Yvonne Perrie have been appointed as Commissioners of the CHM for four years, in accordance with the Cabinet Office Code of Governance for Public Appointments.
The CHM provides independent expert advice to ministers on the safety, quality and efficacy of medicines, and on adverse reactions including those reported under the Yellow Card Scheme. It is an advisory non-departmental public body, sponsored by the Department of Health and Social Care.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Non-Viral Drug Delivery Systems: Focus on Intracellular Technologies and Intracellular Biologics Market, 2021-2030 report features an extensive study of the current landscape and the likely future opportunities in intracellular drug delivery technologies market for the next 10 years.
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for intracellular drug delivery technologies. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2021-2030.
Global Parkinson s Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis
April 27, 2021 06:28 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
The global PD market is forecast to experience significant growth during the forecast period; global sales are expected to increase from $3.5B in 2019 to $11.5B in 2029, at a Compound Annual Growth Rate (CAGR) of 12.6%. This growth will be driven by the launch of 17 late-stage pipeline products.
The highest selling drugs are expected to be: Roche/Prothena s PRX-002 followed by Novo Nordisk s Victoza. PRX-002 is a mAb with disease-modifying properties. KOLs were optimistic about this drug and suggested it may revolutionize PD treatment. Also, the MOA of Victoza was highly regarded as a potential neuroprotective drug in addition to its established high safety profile.
Drug Delivery Systems industry associations and research organizations
Product managers, Drug Delivery Systems industry administrator, C-level executives of the industries
Market Research and consulting firms
Key Questions Answered in This Report:
Which Trends Are Causing These Developments?
Who Are the Global Key Players in Drug Delivery Systems Market?
What’ s Their Company Profile, Their Product Information, Contact Information?
What Was Global Market Status of Drug Delivery Systems Market?
What Was Capacity, Production Value, Cost, and PROFIT of Drug Delivery Systems Market?
Whats Market Analysis of Drug Delivery Systems Market by Taking Applications and Types in Consideration?
What Will Be the Estimation of Cost and Profit?